Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Understanding and treating the inflammatory adverse events of cancer immunotherapy
Michael Dougan, Adrienne Luoma, Stephanie K. Dougan, et al.
Cell (2021) Vol. 184, Iss. 6, pp. 1575-1588
Open Access | Times Cited: 207

Showing 1-25 of 207 citing articles:

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Golnaz Morad, Beth A. Helmink, Padmanee Sharma, et al.
Cell (2021) Vol. 184, Iss. 21, pp. 5309-5337
Open Access | Times Cited: 1065
Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 441
Immune mechanisms of toxicity from checkpoint inhibitors
S. Jennifer Wang, Stephanie K. Dougan, Michael Dougan
Trends in cancer (2023) Vol. 9, Iss. 7, pp. 543-553
Open Access | Times Cited: 87
Targeted modulation of immune cells and tissues using engineered biomaterials
Parisa Yousefpour, Kaiyuan Ni, Darrell J. Irvine
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 2, pp. 107-124
Open Access | Times Cited: 83
Harnessing big data to characterize immune-related adverse events
Ying Jing, Jingwen Yang, Douglas B. Johnson, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 269-280
Closed Access | Times Cited: 79
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis
Zhenjie Wu, Qi Chen, Le Qu, et al.
European Urology (2022) Vol. 81, Iss. 4, pp. 414-425
Open Access | Times Cited: 72
Advancing CAR T cell therapy through the use of multidimensional omics data
Jingwen Yang, Yamei Chen, Ying Jing, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 211-228
Closed Access | Times Cited: 65
Immunologic tumor microenvironment modulators for turning cold tumors hot
Gholamreza Khosravi, Samaneh Mostafavi, Sanaz Bastan, et al.
Cancer Communications (2024) Vol. 44, Iss. 5, pp. 521-553
Open Access | Times Cited: 59
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
Lingjiao Meng, Haotian Wu, Jiaxiang Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 56
The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Qingyu Lin, Xingwen Wang, Ying Hu
Cancer Letters (2023) Vol. 569, pp. 216318-216318
Open Access | Times Cited: 53
A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts
Qianhe Ren, Pengpeng Zhang, Haoran Lin, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 49
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Roel Polak, Elisa T. Zhang, Calvin J. Kuo
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 523-539
Closed Access | Times Cited: 44
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Muni Hu, Xiaolin Lin, Tiantian Sun, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 25
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
Jingting Wang, Yan Ma, Haishan Lin, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 24
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations
Layal Rached, Ariane Laparra, Madona Sakkal, et al.
Cancer Treatment Reviews (2024) Vol. 127, pp. 102751-102751
Open Access | Times Cited: 22
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
Jia Luo, Jason Beattie, Paige Fuentes, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 10, pp. 1759-1764
Open Access | Times Cited: 76
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
Joseph W. Fischer, Nirjal Bhattarai
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 72
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
Ying Jing, Xue Chen, Kunyan Li, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003779-e003779
Open Access | Times Cited: 64
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Adrià Archilla‐Ortega, Carla Domuro, Juan Martín-Liberal, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 63
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
Francesco Cortiula, Bart Reymen, Solange Peters, et al.
Annals of Oncology (2022) Vol. 33, Iss. 9, pp. 893-908
Open Access | Times Cited: 63
Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Runci Wang, Anvita Singaraju, Kathryne E. Marks, et al.
Science Immunology (2023) Vol. 8, Iss. 85
Open Access | Times Cited: 37
A neutrophil mimicking metal-porphyrin-based nanodevice loaded with porcine pancreatic elastase for cancer therapy
Tingting Cui, Yu Zhang, Geng Qin, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 36
Checkpoint inhibitor hepatotoxicity: pathogenesis and management
Morven Cunningham, Rohit Gupta, Marcus O. Butler
Hepatology (2023) Vol. 79, Iss. 1, pp. 198-212
Closed Access | Times Cited: 25
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology
Carlo G. Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2055-2076
Closed Access | Times Cited: 13
Targeting of TAMs: can we be more clever than cancer cells?
Julia Kzhyshkowska, Jiaxin Shen, Irina Larionova
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 12, pp. 1376-1409
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top